These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1346604)

  • 41. Why women are not receiving anti Rh prophylaxis.
    Tovey LA
    Br Med J (Clin Res Ed); 1987 Jun; 294(6585):1485. PubMed ID: 3038255
    [No Abstract]   [Full Text] [Related]  

  • 42. Prevention of Rh(D) alloimmunization: a cost-benefit analysis.
    Baskett TF; Parsons ML
    CMAJ; 1990 Feb; 142(4):337-9. PubMed ID: 2154307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of post-transfusion RhD immunization using red cell exchange and intravenous anti-D immunoglobulin.
    Laspina S; O'riordan JM; Lawlor E; Murphy WG
    Vox Sang; 2005 Jul; 89(1):49-51. PubMed ID: 15938740
    [No Abstract]   [Full Text] [Related]  

  • 44. Compliance with postpartum Rh isoimmunization prophylaxis in Alberta.
    Huchcroft S; Gunton P; Bowen T
    CMAJ; 1985 Nov; 133(9):871-5. PubMed ID: 2996738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization.
    de la Cámara C; Arrieta R; González A; Iglesias E; Omeñaca F
    N Engl J Med; 1988 Feb; 318(8):519-20. PubMed ID: 3123931
    [No Abstract]   [Full Text] [Related]  

  • 46. Fifty years of RhD immunoglobulin (anti-D) therapy in Australia: celebrating a public health success story.
    Thyer J; Wong J; Thomson A; Bell B; Hyland C; Challis D
    Med J Aust; 2018 Oct; 209(8):336-339. PubMed ID: 30309307
    [No Abstract]   [Full Text] [Related]  

  • 47. Rho (D) immune globulin i.v. for prevention of Rh isoimmunization and for treatment of ITP.
    Med Lett Drugs Ther; 1996 Jan; 38(966):6-8. PubMed ID: 8544794
    [No Abstract]   [Full Text] [Related]  

  • 48. [Weak D (Du) phenotype and pregnancy].
    Stefanova A
    Akush Ginekol (Sofiia); 2005; 44(1):54-6. PubMed ID: 15853015
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical high-risk designation does not predict excess fetal-maternal hemorrhage.
    Ness PM; Baldwin ML; Niebyl JR
    Am J Obstet Gynecol; 1987 Jan; 156(1):154-8. PubMed ID: 3026183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin.
    Thornton JG; Page C; Foote G; Arthur GR; Tovey LA; Scott JS
    BMJ; 1989 Jun; 298(6689):1671-3. PubMed ID: 2547468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Mechanism of action of anti-D-gamma globulin in preventing rhesus alloimmunization in the pregnant woman and hemolytic disease of the newborn infant].
    Vŭlcheva B; Spasova K
    Akush Ginekol (Sofiia); 1985; 24(2):73-6. PubMed ID: 2990248
    [No Abstract]   [Full Text] [Related]  

  • 52. [Recommendations for clinical practice. Prevention in maternofetal Rh immunization (December 2005)].
    Collège National des Gynécologues et Obstétriciens Français
    Gynecol Obstet Fertil; 2006 Apr; 34(4):360-5. PubMed ID: 16644259
    [No Abstract]   [Full Text] [Related]  

  • 53. ACOG Practice Bulletin No. 75: Management of alloimmunization during pregnancy.
    American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2006 Aug; 108(2):457-64. PubMed ID: 16880320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prenatal Rh-immune prophylaxis with 300 micrograms immune globulin anti-D in the 28th week of pregnancy.
    Trolle B
    Acta Obstet Gynecol Scand; 1989; 68(1):45-7. PubMed ID: 2552740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Prenatal immunoglobulin prevention in Rh(D)-negative nonsensitized pregnant women].
    Katsulov A
    Akush Ginekol (Sofiia); 1997; 36(2):1-2. PubMed ID: 9471891
    [No Abstract]   [Full Text] [Related]  

  • 56. Non-invasive prenatal diagnosis and determination of fetal Rh status.
    van der Schoot CE; Hahn S; Chitty LS
    Semin Fetal Neonatal Med; 2008 Apr; 13(2):63-8. PubMed ID: 18249590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Prevention of Rh immunization. II. Management of the risk during the second half of pregnancy and postpartum].
    Larsen JF; Bock JE; Jørgensen JR
    Ugeskr Laeger; 2004 Aug; 166(36):3078-83. PubMed ID: 15387304
    [No Abstract]   [Full Text] [Related]  

  • 58. RhD hemolytic disease of the newborn.
    Bowman JM
    N Engl J Med; 1998 Dec; 339(24):1775-7. PubMed ID: 9845715
    [No Abstract]   [Full Text] [Related]  

  • 59. [Current viewpoints in the anti-D prevention of rhesus alloimmunization in the pregnant woman and of hemolytic disease of the newborn infant (a review of the literature)].
    Spasova K; Vŭlcheva B
    Akush Ginekol (Sofiia); 1986; 25(3):84-90. PubMed ID: 3019168
    [No Abstract]   [Full Text] [Related]  

  • 60. [Prevention of maternal RhD isoimmunization with anti-D gamma isoimmunization].
    Baptista-González HA; Rosenfeld-Mann F; Leiss-Márquez T
    Salud Publica Mex; 2001; 43(1):52-8. PubMed ID: 11270285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.